CX Institutional’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$314K Sell
1,384
-901
-39% -$160K 0.01% 609
2026
Q1
$394K Sell
2,285
-57
-2% -$10.6K 0.01% 520
2025
Q4
$467K Sell
2,342
-1,982
-46% -$360K 0.01% 440
2025
Q3
$677K Sell
4,324
-27
-0.6% -$4.29K 0.02% 362
2025
Q2
$660K Buy
4,351
+1,232
+39% +$164K 0.02% 320
2025
Q1
$469K Sell
3,119
-113
-3% -$18.9K 0.02% 381
2024
Q4
$597K Sell
3,232
-112
-3% -$21.6K 0.02% 319
2024
Q3
$659K Sell
3,344
-154
-4% -$32K 0.03% 337
2024
Q2
$723K Sell
3,498
-1
-0% -$227 0.03% 322
2024
Q1
$948K Buy
3,499
+20
+0.6% +$4.78K 0.05% 288
2023
Q4
$822K Buy
3,479
+133
+4% +$26.2K 0.04% 282
2023
Q3
$656K Buy
3,346
+19
+0.6% +$3.9K 0.04% 297
2023
Q2
$700K Buy
3,327
+170
+5% +$33.8K 0.04% 318
2023
Q1
$632K Buy
3,157
+11
+0.3% +$2.49K 0.03% 331
2022
Q4
$686K Buy
3,146
+38
+1% +$8.3K 0.04% 324
2022
Q3
$612K Buy
3,108
+5
+0.2% +$1.08K 0.04% 316
2022
Q2
$664K Sell
3,103
-7
-0.2% -$1.71K 0.05% 279
2022
Q1
$883K Buy
3,110
+2
+0.1% +$617 0.07% 229
2021
Q4
$1.17M Buy
3,108
+2
+0.1% +$777 0.09% 190
2021
Q3
$1.28M Sell
3,106
-2
-0.1% -$831 0.1% 192
2021
Q2
$1.15M Hold
3,108
0.09% 197
2021
Q1
$901K Hold
3,108
0.08% 201
2020
Q4
$777K Hold
3,108
0.07% 213
2020
Q3
$704K Buy
3,108
+1
+0% +$208 0.08% 189
2020
Q2
$542K Buy
3,107
+7
+0.2% +$1.12K 0.07% 187
2020
Q1
$391K Hold
3,100
0.06% 191
2019
Q4
$474K Hold
3,100
0.08% 152
2019
Q3
$410K Sell
3,100
-14
-0.4% -$1.88K 0.07% 173
2019
Q2
$442K Buy
3,114
+14
+0.5% +$1.9K 0.07% 166
2019
Q1
$450K Hold
3,100
0.08% 162
2018
Q4
$351K Buy
+3,100
New +$388K 0.07% 145

Other funds holding CRL

CX Institutional's CRL Position: Q2 2026 in Review

CX Institutional reduced its Charles River Laboratories (CRL) stake by 39% in Q2 2026, selling an estimated $160K and leaving 1,384 shares worth $314K. The position accounts for 0.01% of the portfolio, ranked #609.

CX Institutional first reported a position in CRL in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.28M in Q3 2021. 71 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • CX Institutional held 1,384 shares of Charles River Laboratories worth $314K as of Q2 2026.
  • CX Institutional sold 901 Charles River Laboratories shares in Q2 2026, an estimated $160K.
  • Charles River Laboratories made up 0.01% of CX Institutional's portfolio in Q2 2026, its #609 holding.
  • CX Institutional first reported a position in Charles River Laboratories in Q4 2018 and has held it in 31 quarters since.
  • CX Institutional's Charles River Laboratories position peaked at $1.28M in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.